CHDIChild Health and Development Institute (Farmington, CT)
CHDIClinton Hunter Development Initiative (sustainable development initiative; William J. Clinton Foundation; New York, NY)
CHDICure Huntington's Disease Initiative
CHDICancer Health Disparities Initiative (University of Wisconsin Carbone Cancer Center; Madison, WI)
References in periodicals archive ?
While CHDI mostly conducts discovery and development research, one recent study offers a good illustration of how disease foundations have tried to improve the pace of translational research by working with CROs to validate previously published data.
A pharmacodynamic biomarker could be an important contribution to our clinical development efforts, and we look forward to working with KineMed and CHDI to evaluate KineMed's biomarker platform in our Huntington's disease program," said Frank Bennett, Ph.
11 August 2011 - US-based company Isis Pharmaceuticals Inc (NASDAQ: ISIS) and CHDI Foundation Inc, a scientific organisation exclusively dedicated to rapidly discovering and developing therapies, announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington's disease (HD).
Biotechnology company Galapagos NV (Euronext: GLPG) and CHDI Foundation Inc, a non-profit virtual biotech pursuing therapies for Huntington's disease, have entered into a new five-year collaboration focused on discovering novel drugs for Huntington's disease.
CHDI and its collaborators have developed a unique series of 20 ES cell lines from genetically modified mouse models that mimic aspects of Huntington's disease.
CHDI is dedicated to researching therapies that could help Huntington's disease patients and our team looks forward to the collaboration with Samaritan.
HAMBURG, Germany, September 11, 2014-Evotcc AG (FRANKFURT: EVT) and CHDI Foundation, Inc.
We are delighted that CHDI, an organization dedicated solely to the quest to discover novel drugs against Huntington's disease, continues to work in partnership with Evotec," said Dr.
Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, and Ono Pharmaceutical.
During 2009 the company entered into several new alliances and contract extensions including Biogen Idec, CHDI (after period-end) and Ono Pharmaceutical.
Galapagos has applied its proprietary target discovery platform in collaborations with the CHDI (for Huntington's disease), the Cystic Fibrosis Foundation and the ALS Foundation.
PPDI and CHDI are high performance diisocyanates earlier introduced by Akzo but then withdrawn.